Pharma Marketing Network

MARCH 20, 2025

With the rapid expansion of digital platforms, evolving patient expectations, and the increasing role of AI-driven marketing, pharmaceutical companies and healthcare brands are allocating more resources to advertising in 2025. The introduction of new drugs, biosimilars, and specialty treatments has led to increased promotional spending.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies HIPAA Biosimilars 59

Pharma Marketing Network

MAY 21, 2025

For example, unbranded resources discussing GLP-1 efficacy or biosimilar adoption trends often outperform product-specific messaging, especially early in the funnel. Use opt-in consent language that aligns with GDPR and HIPAA. Conclusion In 2025, Lead Gen in pharma marketing is less about forms and more about frameworks.

HIPAA 52

HIPAA Biosimilars 52

FDA Law Blog: Biosimilars

MAY 26, 2025

The political battle went into gear on January 28, 2025, with an Executive Order titled Protecting Children from Chemical and Surgical Mutilation. The EO and DOJ memo were followed by a May 1, 2025 announcement of a report from the U.S. The gray box at the top of the document at this link shows the change in position.

Labelling 59

Labelling HIPAA Documentation Immunity 59